Many human-relevant technologies that will improve safety and reduce preclinical animal tests already exist, and many more innovative methods are in development. Earlier this year, the Johns Hopkins Bloomberg School of Public Health announced that researchers have developed “mini-brains” made up of human brain neurons and cells. The “mini-brains” may be superior to animal experiments
and could dramatically improve preclinical drug testing for Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and even autism.
Physicians Committee scientists and staff are developing and promoting innovative modern technologies and influencing the laws and policies that govern their use. Ultimately, the Physicians Committee’s work in this area will lead to better outcomes for patients and a shift away from animal testing for human drugs.
